Deja Robinson

Islatravir: evaluation of clinical development for HIV and HBV

Islatravir, Pipeline Research / By

Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) that disrupts HIV reverse transcriptase through multiple mechanisms and retains a 3’OH group, unlike other approved NtRTIs. The drug has demonstrated high potency and tolerability in both in vitro and clinical studies. The review covers the historical development of ISL, its mechanisms of action against […]

Islatravir: evaluation of clinical development for HIV and HBV Read More »

Modeling of HIV-1 prophylactic efficacy and toxicity with islatravir shows non-superiority for oral dosing, but promise as a subcutaneous implant

Islatravir, Pipeline Research / By

HIV prevention with pre-exposure prophylaxis (PrEP) is crucial, but daily oral adherence can be challenging. Long-acting (LA) PrEP formulations, such as islatravir (ISL), offer a solution with less frequent dosing. A mathematical model using phase II trial data found that ISL implants at 56–62 mg effectively reduce HIV risk without adversely affecting lymphocyte counts, whereas

Modeling of HIV-1 prophylactic efficacy and toxicity with islatravir shows non-superiority for oral dosing, but promise as a subcutaneous implant Read More »

Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques

Islatravir, Pipeline Research / By

Treatment nonadherence in people living with HIV  poses significant risks, including drug resistance, disease progression, and increased morbidity and mortality. Long-acting antiretroviral therapies, such as islatravir (ISL), offer a potential solution by minimizing the need for frequent dosing. This study demonstrates that a subdermal long-acting nanofluidic implant delivering ISL effectively reduces viral load in SHIV-infected

Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques Read More »

Current status of the small molecule anti-HIV drugs in the pipeline or recently approved

Apretude, Islatravir, Pipeline Research / By

HIV/AIDs presents significant treatment challenges due to increasing resistance to current antiretroviral drugs. This resistance is exacerbated in low- and middle-income countries due to drug misuse, inadequate drug supply, and poor treatment monitoring. Despite these challenges, there has been progress in developing new ARV drugs targeting various components of HIV. This review, updated as of

Current status of the small molecule anti-HIV drugs in the pipeline or recently approved Read More »

Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir–Rilpivirine in People With HIV Who Are Virally Unsuppressed

Approved Medications Research, Apretude / By

According to preliminary data, individuals with HIV who are not able to achieve viral suppression with oral treatments may benefit from long-acting injectable cabotegravir and rilpivirine (LA-CAB/RPV). Utilizing the Consolidated Framework for Implementation Research, a research conducted at Ward 86 in San Francisco examined patient, provider, and contextual characteristics that impact the implementation of LA-CAB/RPV.

Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir–Rilpivirine in People With HIV Who Are Virally Unsuppressed Read More »

Long-Acting Injectable Pre-Exposure Prophylaxis Perceptions and Preferences Among Transgender and Nonbinary Young Adults in the United States

Apretude / By

The United States legalized the use of long-acting injectable pre-exposure prophylaxis for HIV prevention (LAI-PrEP) in 2021. However, little is known about how transgender and nonbinary young adults, a population that faces significant obstacles to HIV prevention, see LAI-PrEP. The study looks at this population’s perceptions of long-acting injectable PrEP’s acceptability, convenience, and efficacy compared

Long-Acting Injectable Pre-Exposure Prophylaxis Perceptions and Preferences Among Transgender and Nonbinary Young Adults in the United States Read More »

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women

Lenacapavir / By

For the prevention of HIV in cisgender women, there are variations in the uptake, adherence, and durability of preexposure prophylaxis. This study tested the effectiveness of subcutaneous lenacapavir and daily oral emtricitabine–tenofovir alafenamide (F/TAF) versus daily oral emtricitabine–tenofovir disoproxil fumarate (F/TDF) in preventing HIV among adolescent girls and young women in South Africa and Uganda.

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women Read More »

Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists: An executive summary

Apretude, Cabenuva / By

Five long-acting (LA) antiretrovirals (ARVs)—cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine—are now available in a few countries for HIV-1 prevention and treatment. To integrate LA ARVs into routine clinical practice, significant changes in HIV-1 care are needed. Consensus recommendations will guide doctors in the effective and safe use of these new, complex agents. These guidelines aim

Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists: An executive summary Read More »

A mixed methods evaluation of pharmacists’ readiness to provide long-acting injectable HIV pre-exposure prophylaxis in California

Approved Medications Research / By

The uptake of pre-exposure prophylaxis (PrEP) remains low among eligible individuals, with some preferring alternatives like long-acting injectable PrEP (LAI-PrEP) over daily oral PrEP. This study investigated the feasibility of offering LAI-PrEP through pharmacies in California, where pharmacists are authorized to provide oral PrEP independently. Using both statistical and qualitative analysis, the study identified factors

A mixed methods evaluation of pharmacists’ readiness to provide long-acting injectable HIV pre-exposure prophylaxis in California Read More »

Identification of Determinants and Implementation Strategies to Increase Long-Acting Injectable PrEP for HIV Prevention Among Latino Men Who Have Sex with Men (MSM)

Apretude / By

In the United States, HIV infections disproportionately afflict Latino men who have sex with men (LMSM). Pre-exposure prophylaxis, or PrEP, has not been widely adopted by LMSM as a means of preventing HIV. Injectable PrEP with a long half-life (LAI-PrEP) may help with behavioral, cognitive, and structural adherence difficulties. The purpose of our study was

Identification of Determinants and Implementation Strategies to Increase Long-Acting Injectable PrEP for HIV Prevention Among Latino Men Who Have Sex with Men (MSM) Read More »

Scroll to Top